| | 1st TNF % (95% CI) | 2nd TNF % (95% CI) |
|---|
Outcome at 3 M defined (n = 96*) |
ASDAS CII | 51 (42; 60) | 41 (31; 50) |
BASDAI50 | 45 (36; 54) | 39 (29; 48) |
ASDAS MII | 33 (25; 42) | 13 (6; 19) |
ASDAS LDA | 42 (32; 51) | 26 (18; 35) |
ASDAS inactive | 19 (12; 26) | 16 (9; 22) |
Outcome at 6 M defined (n = 79*) |
ASDAS CII | 56 (46; 66) | 35 (26; 45) |
BASDAI50 | 46 (35; 56) | 33 (23; 43) |
ASDAS MII | 32 (22; 41) | 22 (13; 30) |
ASDAS LDA | 41 (30; 51) | 29 (19; 39) |
ASDAS inactive | 11 (5; 18) | 15 (8; 22) |
- Percentages and 95% CI are derived from logistic regression models adjusted for age, gender, and CRP at baseline
- ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Activity Index, LDA low disease activity, ID inactive disease, CII clinically important improvement, MII major important improvement, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50, TNFi tumor necrosis factor inhibitor, M months
- *96 patients had ASDAS and BASDAI outcomes available at baseline and 3 months for both TNFi; 79 patients had ASDAS and BASDAI outcomes available at baseline and 6 months for both TNFi
